# US 2013/0253382 A1 · Targeted enzymatic degradation of quorum-sensing peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253382 A1
- Document ID: US20130253382A1
- Status: Published application
- Kind: A1
- Application number: 13/841,200
- Filed: 2013-03-15
- Published: 2013-09-26
- Earliest claimed: 2012-03-20
- Assignees: KCI Licensing, Inc.
- Inventors: RODOLFO ALARCON; Amy K. McNulty
- Web page: https://patentgrep.com/patent/US20130253382A1

## CPC

- A61L 2/16: using chemical substances
- A61K 38/48: acting on peptide bonds (3.4)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/40: bacterial
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- C07K 14/001: {by chemical synthesis}
- C07K 16/12: against material from bacteria
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods and compositions for the treatment of biofilms and/or the inhibition of biofilm formation. In one embodiment, a biofilm is treated and/or biofilm formation is inhibited by a method comprising contacting a biofilm or a surface with a bifunctional ligand comprising a quorum-sensing-peptide-binding region and a protease-binding region, whereby the biofilm is treated and/or biofilm formation on the surface is inhibited.

## Claims

### Claim 1

A method for treating a biofilm and/or inhibiting biofilm formation comprising contacting a biofilm or a surface with a bifunctional ligand comprising a quorum-sensing-molecule-binding region and a protease-binding region, whereby the biofilm is treated and/or biofilm formation on the surface is inhibited.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biofilm comprises Gram-positive bacteria.

### Claim 3 (depends on 2)

The method of claim 2, wherein the Gram-positive bacteria is one or more of Staphylococcus aureus, Staphylococcus epidermis, Streptococcus pyogenes (group A), Streptococcus species (viridans group), Streptococcus agalactiae (group B), Streptococcus bovis, Streptococcus pneumoniae, Enterococcus species, Bacillus anthracis, Corynebacterium diphtheriae, Listeria monocytogenes, Clostridium tetani, or Clostridium difficile.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biofilm comprises Gram-negative bacteria.

### Claim 5 (depends on 4)

The method of claim 4, wherein the Gram-negative bacteria is one or more of Escherichia coli, Enterobacter species, Proteus mirablis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Salmonella species, Shigella species, Serratia species, Campylobacterjejuni species, Neisseria species, or Branhamella catarrhalis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the surface is a tissue site.

### Claim 7 (depends on 6)

The method of claim 6, wherein the tissue site is in contact with an indwelling medical device.

### Claim 8 (depends on 1)

The method of claim 1, wherein the surface is an indwelling medical device.

### Claim 9 (depends on 8)

The method of claim 8, wherein the indwelling medical device is a catheter or a ventilation tube.

### Claim 10 (depends on 1)

The method of claim 1, wherein the quorum-sensing-peptide-binding region of the bifunctional ligand binds an acyl homoserine lactone (AHL), autoinducing peptide (AIP), γ-butyrolactone, or competence stimulating peptide (CSP).

### Claim 11 (depends on 1)

The method of claim 1, wherein the protease-binding region binds a lactonase.

### Claim 12 (depends on 1)

The method of claim 1, wherein the bifunctional ligand is formulated in a gel or a foam.

### Claim 13 (depends on 1)

The method of claim 1, further comprising contacting the biofilm or the surface with an antibiotic.

### Claim 14 (depends on 1)

The method of claim 1, further comprising contacting the biofilm or the surface with a protease.

### Claim 15 (depends on 1)

The method of claim 1, wherein the biofilm and/or the surface is located in a wound.

### Claim 16 (depends on 15)

The method of claim 15, further comprising applying reduced pressure to the wound.

### Claim 17

A bifunctional ligand comprising a quorum-sensing-molecule-binding region and a protease-binding region.

### Claim 18 (depends on 17)

The bifunctional ligand of claim 17, wherein the quorum-sensing-molecule-binding region binds an acyl homoserine lactone (AHL), autoinducing peptide (AIP), γ-butyrolactone, or competence stimulating peptide (CSP).

### Claim 19 (depends on 17)

The bifunctional ligand of claim 17, wherein the quorum-sensing-molecule-binding region comprises a quorum-sensing molecule receptor or a quorum-sensing molecule receptor fragment.

### Claim 20 (depends on 17)

The bifunctional ligand of claim 17, wherein the quorum-sensing-molecule-binding region comprises an antibody or an antibody fragment that binds a quorum-sensing molecule.

### Claim 21 (depends on 17)

The bifunctional ligand of claim 17, wherein the protease-binding region binds a lactonase.

### Claim 22 (depends on 17)

The bifunctional ligand of claim 17, further comprising a peptide linker between the quorum-sensing-molecule-binding region and the protease-binding region.

### Claim 23 (depends on 17)

A composition comprising a bifunctional ligand of claim 17 and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the composition is formulated as a liquid, gel, or foam.

### Claim 25 (depends on 23)

The composition of claim 23, wherein the composition further comprises an antibiotic.

### Claim 26 (depends on 23)

The composition of claim 23, wherein the composition further comprises a protease.

### Claim 27 (depends on 23)

A kit comprising the composition of claim 23.

### Claim 28 (depends on 27)

The kit of claim 27, further comprising an antibiotic.

### Claim 29 (depends on 27)

The kit of claim 27, further comprising a protease.
